Ngenla Subcutaneous Injection Special Investigation

← catalyst calendar

NCT05602766 · readout in 961 d

Sponsored by Pfizer (industry) · PFE — their whole pipeline →.

Phase

—

Status

Active, not recruiting

Study type

Observational

Enrollment

1actual

Sites

Country

Japan

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

Dates

each axis at the precision it was filed, with the registry's own basis

Date

Filed

Basis

What it is

Start

2023-02-06

actual

When the study began enrolling

Primary completion

2029-04-06

estimated

The date the last participant is measured for the primary outcome — the readout window

Study completion

2029-04-06

estimated

The whole study's end, after follow-up

First posted

2022-11-02

actual

When this record first appeared on the registry

Results posted

—

When the sponsor posted results to the registry

Record updated

2025-10-02

actual

The sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Condition

Growth Hormone Deficiency Without Epiphyseal Closure

Intervention

Drug: NGENLA (Somatrogon)

Primary outcomes

what the primary-completion date above is the date OF

The number of patients reporting Adverse Events (AEs)

measured up to 5 years

Incidence of Glucose metabolism disorders per exposure period

measured up to 5 years

Incidence of Neoplasm per exposure period

measured up to 5 years

Annual growth rate (cm/year)

measured up to 5 years

Growth rate standard deviation score (SDS) for chronological age

measured up to 5 years

Change in height SDS for chronological age and time-course of height SDS for chronological age

measured up to 5 years

Proportion of reported Adverse Events

measured up to 5 years

Permalink · PFE's whole pipeline · Catalyst calendar · Every registered study · What changed